Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LORELY: Loncastuximab Tesirine after CAR T-cell failure in DLBCL/HGBCL
2022-001147-24Phase 2Active
- Sponsor
- Humanitas Research Hospital
- Start
- Jan 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and mature B-cell lymphoma, sponsored by Humanitas Research Hospital. Primary endpoint: Overall response rate (ORR). Started Jan 2023; status: active.
02
Drugs
loncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomamature B-cell lymphoma
Beyond the preview
Go deeper on 2022-001147-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001147-24.